Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 1;150(1):e2021056021.
doi: 10.1542/peds.2021-056021.

Safety of Live-Attenuated Vaccines in Children Exposed to Biologic Response Modifiers in Utero

Ousseny Zerbo  1 , Sharareh Modaressi  1 , Kristin Goddard  1 , Edwin Lewis  1 , Darios Getahun  2   3 , Kristin K Palmsten  4 , Candace C Fuller  5 , Bradley Crane  6 , James G Donahue  7 , Matthew F Daley  8 , Lisa A Jackson  9 , A Patricia Wodi  10 , Michael M McNeil  11 , Nicola P Klein  1
Affiliations

Safety of Live-Attenuated Vaccines in Children Exposed to Biologic Response Modifiers in Utero

Ousseny Zerbo et al. Pediatrics. .

Abstract

Objectives:: To estimate the prevalence of biological response modifiers (BRM) use during pregnancy and compare clinical outcomes in infants, live-attenuated immunization coverage and adverse events of special interest (AESI) following immunization.

Methods:: We conducted a retrospective cohort study among pregnant people between 2006 – 2017 and children born from these pregnancies within the Vaccine Safety Datalink. We estimated the proportion of women who used BRM during pregnancy overall and by year of pregnancy onset. We compared clinical outcomes, live-attenuated vaccination coverage, and AESI occurring in specific risk intervals following immunization in children exposed and unexposed in utero to BRM.

Results:: Of the 1,205,416 pregnant people, 2,243 used BRM (19/10,000), which increased from 8/10,000 in 2006 to 46/10,000 pregnant people in 2017. The most frequently dispensed or prescribed BRM were etanercept (35.9%), anakinra (23.2%), adalimumab (21.4%) and infliximab (19.9%). Except for pneumonia, clinical outcomes of interest were rare among exposed and unexposed children to BRM. Proportions of clinical outcomes were similar between both groups. A lower proportion of children exposed to BRM receive rotavirus vaccines by age 12 months compared with unexposed children (79.5% vs. 85.4%). AESI with measles-containing vaccines or rotavirus vaccines were rare and proportions of these were similar among exposed and unexposed children.

Conclusion:: In utero exposure to BRM was not associated with an increased risk of clinically significant infections or adverse events following live-attenuated vaccines. These data provide reassurance that children exposed in utero to BRM can receive live-attenuated vaccines on the same schedule as other children.

PubMed Disclaimer

Conflict of interest statement

Dr. Klein has received research support from Sanofi Pasteur, GSK, Merck, Pfizer, and Protein Sciences (now Sanofi Pasteur) for unrelated studies. Dr. Getahun has received research grant support from NICHD, the Garfield Memorial Fund, Hologic Inc and Bayer for unrelated studies. Dr. Donahue reports grants from Janssen Global Services, LLC, outside the submitted work. Dr. Fuller has received research funding from Pfizer and Johnson & Johnson for unrelated studies.

All other co-authors have no conflicts of interest.

Figures

Figure 1:
Figure 1:
Prevalence of Biological Response Modifiers (BRM) Among Pregnant people. Vaccine Safety Datalink 2006 – 2017
See this image and copyright information in PMC

References

    1. Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278(4):369–395. - PubMed
    1. Betteridge JD, Armbruster SP, Maydonovitch C, Veerappan GR. Inflammatory bowel disease prevalence by age, gender, race, and geographic location in the U.S. military health care population. Inflamm Bowel Dis. 2013;19(7):1421–1427. - PubMed
    1. Lerner A, Jeremias P, T M. The World Incidence and Prevalence of Autoimmune Diseases is Increasing. International Journal of Celiac Disease. 2015;3(4):151–155.
    1. Dinse GE, Parks CG, Weinberg CR, Co CA, Wilkerson J, Zeldin DC, et al. Increasing Prevalence of Antinuclear Antibodies in the United States. Arthritis Rheumatol. 2020;72(6):1026–1035. - PMC - PubMed
    1. Le Saux N, Canadian Paediatric Society ID, Immunization C. Biologic response modifiers to decrease inflammation: Focus on infection risks. Paediatr Child Health. 2012;17(3):147–154. - PMC - PubMed

Publication types